NEW YORK (360Dx) – Co-Diagnostics ended its first day as a public traded firm with its shares down about 3 percent on the Nasdaq.

The firm went public on Wednesday with an offering of more than 1.1 million shares at $6 per share. Trading on the Nasdaq Capital Market under ticker symbol CODX, its shares ended the day at $5.81 per share.

Total gross proceeds from IPO was $7.1 million, the firm said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Under a proposed spending bill, the US National Institutes of Health would see an additional $3 billion in funding.

Researchers from the University of Oxford and the University of Sydney sequenced numerous platypus genomes to study their population history.

Robert Redfield, the new pick to lead the US Centers for Disease Control and Prevention, has faced criticism for some of his work.

In Nature this week: sequenced genomes of five additional Neanderthals, and more.